Kazia Therapeutics Limited (KZIA)
NASDAQ: KZIA · Real-Time Price · USD
11.40
+0.41 (3.73%)
At close: Jun 8, 2026, 4:00 PM EDT
11.35
-0.05 (-0.44%)
After-hours: Jun 8, 2026, 4:10 PM EDT
Kazia Therapeutics Revenue
Kazia Therapeutics had revenue of 14.66M AUD in the half year ending December 31, 2025, with 209,471,328.57% growth. This brings the company's revenue in the last twelve months to 885.77K, down -93.59% year-over-year. In the fiscal year ending June 30, 2025, Kazia Therapeutics had annual revenue of 41.77K, down -98.19%.
Revenue (ttm)
885.77K AUD
Revenue Growth
-93.59%
P/S Ratio
102.86
Revenue / Employee
147,628 AUD
Employees
6
Market Cap
130.27M USD
Revenue Chart
* This company reports financials in AUD.
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Jun 30, 2025 | 41.77K | -2.27M | -98.19% |
| Jun 30, 2024 | 2.31M | 2.31M | 230,745.00% |
| Jun 30, 2023 | 1,000.00 | -24.00K | -96.00% |
| Jun 30, 2022 | 25.00K | -15.16M | -99.84% |
| Jun 30, 2021 | 15.18M | 14.19M | 1,425.93% |
| Jun 30, 2020 | 995.00K | -470.00K | -32.08% |
| Jun 30, 2019 | 1.47M | 1.35M | 1,131.09% |
| Jun 30, 2018 | 119.00K | -130.00K | -52.21% |
| Jun 30, 2017 | 249.00K | -157.00K | -38.67% |
| Jun 30, 2016 | 406.00K | 317.00K | 356.18% |
| Jun 30, 2015 | 89.00K | 2.00K | 2.30% |
| Jun 30, 2014 | 87.00K | -1.03M | -92.18% |
| Jun 30, 2013 | 1.11M | -335.00K | -23.15% |
| Jun 30, 2012 | 1.45M | -578.00K | -28.54% |
| Jun 30, 2011 | 2.03M | 241.00K | 13.51% |
| Jun 30, 2010 | 1.78M | -720.00K | -28.75% |
| Jun 30, 2009 | 2.50M | -10.78M | -81.15% |
| Jun 30, 2008 | 13.28M | -4.01M | -23.20% |
| Jun 30, 2007 | 17.30M | -150.00K | -0.86% |
| Jun 30, 2006 | 17.45M | 56.00K | 0.32% |
| Jun 30, 2005 | 17.39M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Agenus | 123.87M |
| ADC Therapeutics | 79.18M |
| Alpha Cognition | 10.83M |
| Alps Group | 3.74M |
| Spruce Biosciences | 697.00K |
| Connect Biopharma Holdings | 233.00K |
| Genelux | 8.00K |
KZIA News
- 6 days ago - Kazia Therapeutics appoints James Levine as CFO - TheFly
- 6 days ago - Kazia Therapeutics Appoints James Levine as Chief Financial Officer - PRNewsWire
- 13 days ago - Kazia Therapeutics Expands Ongoing Phase 1b Trial of Paxalisib in Advanced Breast Cancer - PRNewsWire
- 7 weeks ago - Kazia Therapeutics appoints Sudha Rao as Chief Scientific Officer - TheFly
- 7 weeks ago - Kazia Therapeutics Strengthens Scientific Leadership with Appointment of Dr. Sudha Rao as Chief Scientific Officer to Lead Next-Generation Oncology Platform - PRNewsWire
- 7 weeks ago - Kazia Therapeutics initiated with a Buy at Laidlaw - TheFly
- 2 months ago - Kazia Therapeutics in-licenses drug development platform from QIMR Berghofer - TheFly
- 2 months ago - Kazia Therapeutics Expands Oncology Platform with First-in-Class SETDB1 Inhibitor Drug Development Platform - PRNewsWire